Boehringer Ingelheim GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boehringer Ingelheim GmbH
Of the 16 products whose Orange Book patent listings have been challenged by the FTC, six have no generic competitors and two faced first generic launches this year. A review of their patent and pricing battles shows the difficulties in developing generics for these complex drugs.
Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip.
Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.
- Other Names / Subsidiaries
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.